South Korea Glucose Intravenous (IV) Solutions Market Insight
Published: 30 July 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
The South Korean market for glucose intravenous (IV) solutions is anticipated to increase at compound yearly growth rate of 5.51% because to rising need for surgical procedures and chronic illness management.
South Korea Glucose Intravenous (IV) Solutions Market Insights Forecasts to 2035
- The South Korea Glucose Intravenous (IV) Solutions Market Size Was Estimated USD 196.4 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 5.51% from 2025 to 2035
- The South Korea Glucose Intravenous (IV) Solutions Market Size is Expected to rise around USD 335.7 Million by 2035
Notable Insights for the South Korea Glucose Intravenous (IV) Solutions Market
- According to solution concentration segmentation, 10% and 50% concentrations are favored for severe hypoglycemia and nutritional support, whilst 5% dextrose predominates for maintenance therapy.
- According to end-user segmentation, ambulatory surgical centers and home care settings are emerging as the fastest-growing segments, with hospitals holding the biggest revenue share.
- Due to growing surgical demand and an older population, the South Korean pharmaceutical industry projects that the local IV fluid market will reach about KRW 525 billion (USD 398 million) in 2025.
- In 2025, JW Life Science's IV fluid sales alone totaled KRW 224.2 billion (USD 169 million), or more than 29% of its overall sales, indicating robust market demand.
Download the eBook (ToC)
Research Methodologies Used to Analyze the South Korea Glucose Intravenous (IV) Solutions Market
The South Korea glucose intravenous solutions market is looked at closely. This is done by talking to people who make these solutions, hospitals and doctors. We also look at what the government and other companies have to say about healthcare. We talk to the people who make the solutions, hospitals and healthcare providers, to see what people want, what products are being used, what the rules are and how companies compete. We also think about how the South Korea glucose intravenous solutions market will change as people’s healthcare needs change, over time until 2035. The South Korea glucose intravenous solutions market is studied carefully to understand it better.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors do a lot of research to understand what is happening in the market. They look closely at what's going on in each industry. They also compare companies to see how they are doing. They try to figure out what will happen in the future with trends and they use data to help businesses make decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the South Korea glucose intravenous (IV) solutions market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in South Korea Glucose Intravenous (IV) Solutions Market
- JW Life Science Co., Ltd.
- HK inno.N Corporation
- CJ CheilJedang Corporation
- Daesang Corporation
- B. Braun Korea
- Fresenius Kabi Korea
- Baxter International Inc.
- Otsuka Pharmaceutical Korea
- Pfizer Korea
- CSL Ltd.
Recent Developments:
- In July 2025, Baxter International Inc. introduced improved digital infusion management solutions that are integrated with its IV-therapy portfolio, enhancing medication safety and streamlining workflow for hospitals that use glucose IV solutions.
- In January 2025, HK Inno. To enhance hospital distribution of injectable and infusion medicines via an improved pharmaceutical logistics network, N Corporation entered a strategic partnership with local healthcare providers.
Market Segmentation:
South Korea Glucose Intravenous (IV) Solutions Market, By Concentration
- 5% Dextrose Injection
- 10% Dextrose Injection
- 25% Dextrose Injection
- 50% Dextrose Injection
South Korea Glucose Intravenous (IV) Solutions Market, By End-User
- Hospitals
- Ambulatory Surgical Centers
- Home Care Settings
- Specialty Clinics
South Korea Glucose Intravenous (IV) Solutions Market, By Packaging Type
- IV Bags (Flexible)
- IV Bottles (Rigid)
- Pre-filled Syringes
Expert Views:
The South Korea glucose intravenous solutions market is doing well. It will keep on growing. This is because more people are having surgery and the population is getting older. Also, the South Korea glucose intravenous solutions market is growing because more people are getting diseases. The government is helping by making rules for healthcare. People want South Korea glucose intravenous solutions and that is why the market will keep on growing until 2035.
Author: Govind and Krishna By Decisions Advisors and Consulting